Jun 28 |
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
|
Jun 12 |
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
|
Jun 3 |
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
|
Jun 3 |
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
|
May 25 |
While Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders have made 125% in 1 year, increasing losses might now be front of mind as stock sheds 3.2% this week
|
May 22 |
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
|
May 8 |
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript
|
May 8 |
Rhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...
|
May 8 |
Q1 2024 Rhythm Pharmaceuticals Inc Earnings Call
|
May 8 |
Rhythm Pharmaceuticals, Inc (RYTM) Q1 2024 Earnings Call Transcript
|